DTAB recommends prohibiting pain relief combination S(+) etodolac+paracetamol
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 11, 2024
The Drugs Technical Advisory Board (DTAB) of the Union health ministry has once again recommended prohibiting the manufacture, sale and distribution of pain relief drug combination S(+) etodolac+paracetamol, after considering a sub-committee report.
Let's personalize your content